Patents by Inventor Hideomi KIJIMA

Hideomi KIJIMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10399959
    Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 3, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Masahiro Ikura, Masato Higashino, Hideomi Kijima, Shizuka Ono, Tetsuya Yasuhiro, Takeshi Nagaura
  • Publication number: 20190135755
    Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
  • Publication number: 20170240527
    Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.
    Type: Application
    Filed: August 17, 2015
    Publication date: August 24, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun TAKEUCHI, Satoshi ITADANI, Masahiro IKURA, Masato HIGASHINO, Hideomi KIJIMA, Shizuka ONO, Tetsuya YASUHIRO, Takeshi NAGAURA